About uniQure NV

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

At the moment the company generates 6M USD in revenues.

On its last earning announcement, the company reported a loss of -3.00$ per share.

The book value per share is 8.02$

uniQure NV website

Create a solid portfolio with QURE

Add QURE to your portfolio and optimize it!


Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
6M 93.80% -128M -781.90% -124M -3.00 - - 42M 8.02 -105M -8M -114M